About Us
About Guard Therapeutics
Vision, Business Model & Goal
The Board
Management
Research
Kidney disease
Science
Pipeline
RMC-035
GTX Peptides
Investor Relations
Financial calender
Financial reports
Share information
Corporate governance
General meetings
Rights Issue 2025
Newsroom
Press releases
Event calender
Analyses and presentations
Subscribe
Contact
Swe
Search
Novel Therapies Targeting Kidney Disease
Latest Press Releases
Guard Therapeutics presents additional AKITA results at leading U.S. nephrology conference
Read more
Guard Therapeutics to present at upcoming investor conferences
Read more
Guard Therapeutics publishes interim report January–June 2025
(regulatory)
Read more
Press releases
28 Aug 2025
Guard Therapeutics presents additional AKITA results at leading U.S. nephrology conference
Read more
22 Aug 2025
Guard Therapeutics to present at upcoming investor conferences
Read more
21 Aug 2025 · Regulatory information
Guard Therapeutics publishes interim report January–June 2025
Read more
05 Jun 2025
Guard Therapeutics announces completion of patient enrollment in Phase 2b POINTER study
Read more
Show more
In focus
17 Oct 2024 / Presentation
Guard presents at Redeye Theme "Cardiovascular & Metabolic Diseases Event 2024"
Read more
23 Sep 2024 / Presentation
CEO Tobias Agervald appears on BiotechTV
Read more
19 Sep 2024 / Presentation
Presentation at Pareto Securities' 15th Annual Healthcare Conference
Read more
30 Jan 2024 / Presentation
Guard Therapeutics R&D update January 30, 2024
Read more
Show more
Upcoming events
16 Sep 2025
Guard presents at Paretos 16th Annual Health Conference, September 16th
09 Oct 2025
Guard presents at Redeye Investor Forum - Gothenburg October 9th
03 Nov 2025
Guard attends Bio-Europe, Vienna, November 3–5
13 Nov 2025
Interim report January-September 2025
Read more
Show more
Event calendar
/
Financial calendar